Patents Assigned to Alcon Manufacturing, Ltd.
  • Publication number: 20080057072
    Abstract: Antagonists of cation-independent mannose 6-phosphate/insulin-like growth factor-II receptor are provided for attenuation of CTGF signaling in a method of down-regulation of receptor signaling and downstream decreased signaling of connective tissue growth factor in ocular disorders involving inappropriate CTGF signaling. Ocular disorders involving inappropriate CTGF signaling include ocular hypertension, glaucoma, glaucomatous retinopathy, optic neuropathy, macular degeneration, diabetic retinopathy, choroidal neovascularization, and proliferative vitreoretinopathy, for example. Such disorders are treated by administering antagonists of the present invention.
    Type: Application
    Filed: August 30, 2007
    Publication date: March 6, 2008
    Applicant: ALCON MANUFACTURING, LTD.
    Inventors: Allan R. SHEPARD, Debra L. FLEENOR, Abbot F. CLARK, Najam A. SHARIF
  • Publication number: 20080051361
    Abstract: RNA interference is provided for inhibition of gremlin in intraocular pressure-related conditions, including ocular hypertension and glaucoma such as normal tension glaucoma and open angle glaucoma.
    Type: Application
    Filed: August 24, 2007
    Publication date: February 28, 2008
    Applicant: ALCON MANUFACTURING, LTD.
    Inventors: Jon Chatterton, Abbot Clark
  • Publication number: 20080033184
    Abstract: Disclosed is a method of making a 1-alkylindazole comprising reacting a 1-acylindazole with a first reducing agent, and contacting the resulting mixture with an acid anhydride or acyl halide, and with pyridine or a 4-dialkylaminopyridine or a combination of pyridine and a 4-dialkylaminopyridine, to form a hemiaminal ester and reacting the hemiaminal ester with a second reducing agent to form a 1-alkylindazole. Also disclosed are intermediates for the synthesis of 1-alkylindazoles.
    Type: Application
    Filed: August 1, 2007
    Publication date: February 7, 2008
    Applicant: ALCON MANUFACTURING, LTD.
    Inventors: Pete Delgado, W. Dennis Dean, Raymond E. Conrow
  • Publication number: 20080033183
    Abstract: Described are methods of making pyranoindazoles comprising reacting with a reducing agent a protected halohydrin comprising a secondary carbamate to form a pyranoindazole. In preferred embodiments the secondary carbamate is a benzyl carbamate. Also preferred are embodiments wherein the reacting is preceded by reacting a protected halohydrin with a first organometallic compound. The pyranoindazoles thus formed by the described methods are preferably pharmaceutically active products.
    Type: Application
    Filed: August 1, 2007
    Publication date: February 7, 2008
    Applicant: ALCON MANUFACTURING, LTD.
    Inventor: Raymond E. CONROW
  • Publication number: 20080025973
    Abstract: Antagonists of S1P3 (Edg-3) receptors are provided for attenuation of Smad signaling in a method of down-regulation of receptor signaling and downstream decreased production of connective tissue growth factor in ocular disorders involving CTGF accumulation. Ocular disorders involving inappropriate CTGF accumulation include ocular hypertension, glaucoma, glaucomatous retinopathy, optic neuropathy, macular degeneration, diabetic retinopathy, choroidal neovascularization, proliferative vitreoretinopathy and ocular wound healing, for example. Such disorders are treated by administering antagonists of the present invention.
    Type: Application
    Filed: July 25, 2007
    Publication date: January 31, 2008
    Applicant: ALCON MANUFACTURING, LTD.
    Inventors: Debra L. FLEENOR, Allan R. SHEPARD, Iok-Hou PANG
  • Publication number: 20080021548
    Abstract: Disclosed are soft, high refractive index, acrylic materials. These materials, especially useful as intraocular lens materials, contain an aryl acrylic hydrophobic monomer as the single principal device-forming monomer and a tack-reducing macromer additive. In addition to their use as intraocular lens materials, the present materials are also suitable for use in other ophthalmic or otorhinolaryngological devices, such as contact lenses, keratoprostheses, corneal inlays or rings; otological ventilation tubes and nasal implants.
    Type: Application
    Filed: July 20, 2007
    Publication date: January 24, 2008
    Applicant: ALCON MANUFACTURING LTD.
    Inventors: Diana M. Cordova, Mutlu Karakelle, Chance Lehman, Douglas C. Schlueter, Joseph I. Weinschenk
  • Publication number: 20080021129
    Abstract: Disclosed are soft, high refractive index, acrylic materials. These materials, especially useful as intraocular lens materials, contain an aryl acrylic hydrophobic monomer as the single principal device-forming monomer and a tack-reducing macromer additive. In addition to their use as intraocular lens materials, the present materials are also suitable for use in other ophthalmic or otorhinolaryngological devices, such as contact lenses, keratoprostheses, corneal inlays or rings; otological ventilation tubes and nasal implants.
    Type: Application
    Filed: July 20, 2007
    Publication date: January 24, 2008
    Applicant: ALCON MANUFACTURING LTD.
    Inventors: Diana M. Cordova, Mutlu Karakelle, Chance Lehman, Douglas C. Schlueter, Joseph I. Weinschenk
  • Publication number: 20070293475
    Abstract: Aryl tetrahydrobenzazepine derivatives with minimal 5-HT2B activity relative to 5-HT2A and 5-HT2C activity that are useful for treating glaucoma are disclosed.
    Type: Application
    Filed: June 12, 2007
    Publication date: December 20, 2007
    Applicant: ALCON MANUFACTURING LTD.
    Inventors: Suchismita Mohapatra, Mark R. Hellberg, Zixia Feng
  • Publication number: 20070281901
    Abstract: RNA interference is provided for inhibition of tumor necrosis factor ? (TNF?) by silencing TNF? cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNF? converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNF? targets, in particular, is useful for treating patients having a TNF?-related condition or at risk of developing a TNF?-related condition such as the ocular conditions dry eye, allergic conjunctivitis, or ocular inflammation, or such as dermatitis, rhinitis, or asthma, for example.
    Type: Application
    Filed: May 17, 2007
    Publication date: December 6, 2007
    Applicant: Alcon Manufacturing, Ltd.
    Inventors: John Yanni, Jon Chatterton, Diane Senchyna, Daniel Gamache, Steven Miller
  • Publication number: 20070275922
    Abstract: RNA interference is provided for inhibition of IGF1R mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions.
    Type: Application
    Filed: December 29, 2006
    Publication date: November 29, 2007
    Applicant: Alcon Manufacturing, Ltd.
    Inventors: Jon Chatterton, David Bingaman
  • Patent number: 7285553
    Abstract: Compounds with 5HT7 receptor affinity (some of which are novel) useful for lowering IOP, improving blood flow to the optic nerve head and the retina, providing neuroprotection, and treating retinal diseases are disclosed. The Compounds are also useful for treating sleep disorders, depression, and other psychiatric disorders, such as, schizophrenia, anxiety, obsessive compulsive disorder, circadian rhythm disorders, and centrally and peripherally mediated hypertension. Compositions and methods for their use are also disclosed.
    Type: Grant
    Filed: November 2, 2005
    Date of Patent: October 23, 2007
    Assignee: Alcon Manufacturing, Ltd.
    Inventors: Jesse A. May, Thomas R. Dean, Najam A. Sharif, Hwang-Hsing Chen
  • Publication number: 20070232675
    Abstract: The invention concerns in one embodiment a method of treating glaucoma or elevated intraocular pressure comprising administering a pharmaceutically effective amount of a composition comprising at least one prenyltransferase inhibitor. In another embodiment, the invention concerns a composition for the treatment of elevated intraocular pressure and glaucoma comprising a pharmaceutically effective amount of a prenyltransferase inhibitor.
    Type: Application
    Filed: March 28, 2007
    Publication date: October 4, 2007
    Applicant: ALCON MANUFACTURING, LTD.
    Inventors: Allan Shepard, Debra Fleenor
  • Publication number: 20070203174
    Abstract: Described are methods for the treatment of ocular hypertension or glaucoma comprising administering a pharmaceutically effective amount of one or more compounds that inhibit the enzyme EgLN-3. Certain embodiments of the invention combine the use of EgLN-3 with other glaucoma treatment agents. The compounds of the invention may be formulated in compositions comprising pharmaceutically acceptable carriers.
    Type: Application
    Filed: February 27, 2007
    Publication date: August 30, 2007
    Applicant: ALCON MANUFACTURING, LTD.
    Inventors: Peter G. KLIMKO, Iok-Hou PANG
  • Publication number: 20070155690
    Abstract: RNA interference, is provided for inhibition of HIF1A mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions.
    Type: Application
    Filed: December 19, 2006
    Publication date: July 5, 2007
    Applicant: Alcon Manufacturing, Ltd.
    Inventors: Jon Chatterton, David Bingaman
  • Publication number: 20070149548
    Abstract: Methods for using (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines are disclosed herein to treat rho kinase-mediated diseases or rho kinase-mediated conditions, including controlling intraocular pressure and treating glaucoma, are disclosed. Ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma, and additionally useful for controlling intraocular pressure, the compositions comprising an effective amount of (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines, are disclosed herein.
    Type: Application
    Filed: December 19, 2006
    Publication date: June 28, 2007
    Applicant: ALCON MANUFACTURING, LTD.
    Inventors: Mark Hellberg, Najam Sharif, Jesse May, Andrew Rusinko, Hwang-Hsing Chen
  • Publication number: 20070149616
    Abstract: The present invention provides methods for identifying a patient at risk for developing AMD by identifying the presence of the Y402H polymorphism or other at risk variants in the complement factor H gene. The present invention further provides methods for treating persons having AMD or at risk for developing AMD as a result of having the Y402H polymorphism or other at risk variants in the complement factor H gene.
    Type: Application
    Filed: December 21, 2006
    Publication date: June 28, 2007
    Applicant: Alcon Manufacturing, Ltd.
    Inventors: Abbot Clark, Allan Shepard
  • Publication number: 20070149473
    Abstract: RNA interference is provided for inhibition of Rho kinase mRNA expression for treating patients with ocular disorders, particularly for treating intraocular pressure, ocular hypertension and glaucoma. Rho kinase mRNA targets include mRNA for ROCK1 and ROCK2.
    Type: Application
    Filed: December 19, 2006
    Publication date: June 28, 2007
    Applicant: Alcon Manufacturing, Ltd.
    Inventors: Jon Chatterton, Abbot Clark
  • Publication number: 20070141170
    Abstract: The present invention provides improved dietary supplements and methods for inhibiting the progression of macular degeneration and promoting healthy vision, while at the same time maintaining general health. The dietary supplements of the invention contain vitamin E and carotenoids in the form of Vitamin A, lutein and/or zeaxanthine. The dietary supplements of the invention further contain Vitamin C, copper and zinc and may also contain such ingredients as rosemary, DHA, and other vitamins and minerals.
    Type: Application
    Filed: December 20, 2006
    Publication date: June 21, 2007
    Applicant: ALCON MANUFACTURING, LTD.
    Inventor: JOHN LANG
  • Patent number: 7220546
    Abstract: Methods for diagnosing glaucoma and for screening therapeutic agents for their usefulness in treating glaucoma are disclosed.
    Type: Grant
    Filed: September 10, 2003
    Date of Patent: May 22, 2007
    Assignees: Alcon Manufacturing, Ltd., University of North Texas Health Science Center
    Inventors: Abbot F. Clark, Robert J. Wordinger
  • Patent number: 7169767
    Abstract: The present invention is directed to ophthalmic compositions containing a gelling amount of a combination of galactomannan polysaccharides and borates. The compositions gel or partially gel upon administration to the eye. The present invention also discloses methods of topical ophthalmic administration of the compositions to the eye.
    Type: Grant
    Filed: November 24, 2004
    Date of Patent: January 30, 2007
    Assignee: Alcon Manufacturing, Ltd.
    Inventor: Bahram Asgharian